Search Results
Your search for ,iII matches 9601 pages
Showing 1701 - 1750CARTITUDE-4: Ciltacabtagene Autoleucel Beneficial in Early Myeloma Relapse
Compared with the standard of care for relapsed multiple myeloma, a single infusion of ciltacabtagene autoleucel was associated with a significant 74% reduction in the risk of disease progression in patients with lenalidomide-refractory multiple myeloma after one to three relapses, the phase III...
Expert Point of View: Alexey Danilov, MD, PhD
Alexey Danilov, MD, PhD, Co-Director, Toni Stephenson Lymphoma Center and Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, commented on the phase III ALPINE trial comparing ibrutinib and zanubrutinib in patients...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Expert Point of View: Joseph C. Alvarnas, MD
“Pediatric acute lymphoblastic leukemia (ALL) is the paradigmatic success story in hematology,” said Joseph C. Alvarnas, MD, Professor in the Department of Hematology and Hematopoietic Cell Transplant, Vice President of Government Affairs, and Chief Clinical Advisor for AccessHope at City of Hope...
Blinatumomab Improves Survival in MRD-Negative, B-Cell ALL
The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...
CAR T-Cell Therapy vs Chemoimmunotherapy in Second-Line Treatment of Resistant Large B-Cell Lymphoma
New research has confirmed the superiority of lisocabtagene maraleucel over the standard of care for the second-line treatment of primary refractory or early relapsed large B-cell lymphoma, according to data presented by lead study author Jeremy S. Abramson, MD, Associate Professor of Medicine at...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
Hematologic Oncology 2023 Almanac
The past several months have brought significant advances within the field of hematologic oncology. Here we will review some key updates focusing on pivotal clinical trials and new drug approvals. Advances in Lymphoma Presented at the 2023 ASCO Annual Meeting, SWOG S1826 compared nivolumab plus...
Overcoming Financial Toxicity From Cancer
I knew the moment my fingers found a lump in my left breast, in 2018, that it was cancer, and I wondered if I was going to die. My maternal grandmother had been diagnosed with breast cancer when she was 39, the same age I was when I discovered the mass in my breast. She died 5 years later. Divorced ...
Adjuvant Everolimus in Patients With RCC at High Risk of Recurrence
In the phase III EVEREST trial reported in The Lancet, Christopher W. Ryan, MD, and colleagues found that adjuvant everolimus was not associated with a significant improvement in event-free survival vs placebo in patients at high risk of disease recurrence following surgery for renal cell...
Should CDK4/6 Inhibitors Be a First-Line Option for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer?
Two studies presented at the 2023 ASCO Annual Meeting challenge the use of CDK4/6 inhibitors as part of upfront treatment of advanced hormone receptor–positive, HER2-negative breast cancer. The first, the SONIA trial, found that first-line treatment with CDK4/6 inhibitors led to greater toxicity...
Report Highlights Rapid Adoption of Clinical Research Results Into Colon Cancer Chemotherapy Prescribing Patterns
New research published by Ou et al in JNCCN—Journal of the National Comprehensive Cancer Network evaluated how an important analysis on adjuvant chemotherapy for advanced colon cancer impacted prescribing patterns. The IDEA collaboration included more than 12,000 patients with stage III colon...
EBV-Based Screening Methods for Identifying Nasopharyngeal Carcinoma
In a Taiwanese study reported in the Journal of Clinical Oncology, Lou et al compared two methods of Epstein-Barr virus (EBV) screening to identify nasopharyngeal carcinoma. Study Details Blood samples were obtained from 819 incident Taiwanese nasopharyngeal carcinoma cases (including 213 cases of...
For Advanced Nasopharyngeal Cancer, Adjuvant Gemcitabine Plus Cisplatin Favored Over Fluorouracil Plus Cisplatin, Study Reports
In patients with N2 and N3 nasopharyngeal carcinoma, adjuvant treatment with concurrent gemcitabine and cisplatin significantly improved progression-free survival, with acceptable toxicity, over fluorouracil plus cisplatin, according to a phase III trial reported from Sun Yat-sen University Cancer...
Three Studies From ASCO 2023 Focus on Metastatic Castration-Resistant Prostate Cancer
Presented here are summaries of three abstracts from the 2023 ASCO Annual Meeting that are pertinent for patients with metastatic castration-resistant prostate cancer. The first two focus on men with homologous recombinant repair (HRR) gene alterations, including BRCA1/2. In the first study,...
Contribution of MEK Inhibition to Combined BRAF/MEK Inhibitor Treatment in Advanced BRAF-Mutant Melanoma
In part 2 of a phase III trial (COLUMBUS) reported in the Journal of Clinical Oncology, Paolo A. Ascierto, MD, and colleagues found evidence that MEK inhibition contributed to positive outcomes with combination BRAF/MEK inhibitor therapy in advanced BRAF V600–mutant melanoma. Study Details As...
Camrelizumab Plus Rivoceranib vs Sorafenib in Unresectable Hepatocellular Carcinoma
In a largely Asian phase III study (CARES-310) reported in The Lancet, Qin et al found that the combination of camrelizumab and rivoceranib (also known as apatinib) significantly prolonged progression-free and overall survival vs sorafenib in the first-line treatment of unresectable or metastatic...
Long-Term Outcomes With Zanubrutinib vs Ibrutinib in Symptomatic Waldenström’s Macroglobulinemia
Details of the final analysis of the phase III ASPEN trial, which compared zanubrutinib and ibrutinib in symptomatic patients with Waldenström’s macroglobulinemia, were published in the Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, and colleagues. The study supported the September...
Neoadjuvant FOLFOX vs Chemoradiotherapy in Locally Advanced Rectal Cancer
As reported in The New England Journal of Medicine by Deb Schrag, MD, MPH, FASCO, and colleagues, the phase III PROSPECT trial has shown neoadjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) was noninferior in disease-free survival vs chemoradiotherapy among patients with locally advanced...
Gastrointestinal Symptoms May Be Prevalent in Geriatric Female Colorectal Cancer Survivors
About 80% of geriatric female colorectal cancer survivors may experience a range of gastrointestinal symptoms years after receiving a diagnosis and treatment for their tumors, according to a recent study published by Han et al in PLOS ONE. Background While depression, anxiety, and fatigue are...
Liquid Biopsy Assay Demonstrates Effective Early Cancer Detection in Asymptomatic Individuals in Vietnam
Studies show that both the incidence of cancer and mortality rates in Vietnam have tripled over the past 3 decades; in 2020, over 182,560 new cases of cancer were diagnosed in the country, and nearly 123,000 people died from the disease. In addition, most cases—up to 80%—are diagnosed at an...
Addition of Talazoparib to Enzalutamide in the First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer
As reported in The Lancet by Neeraj Agarwal, MD, FASCO, and colleagues, the phase III TALAPRO-2 trial has shown that the addition of talazoparib to enzalutamide improved radiographic progression–free survival vs enzalutamide alone in the first-line treatment of patients with metastatic...
Gilteritinib Maintenance Therapy After Transplantation in Patients With FLT3-ITD AML Who Have Measurable Residual Disease
A new therapeutic option is under study for use in a difficult-to-treat subset of patients with acute myeloid leukemia (AML), according to a presentation during the European Hematology Association (EHA) 2023 Hybrid Congress.1 Exploratory results of the phase III MORPHO trial showed a benefit to the ...
Expert Point of View: Anand Ashwin Patel, MD
As presented at the 2023 ASCO Annual Meeting, the phase III IMerge trial of imetelstat1 and the phase III COMMANDS trial of luspatercept2 met their primary endpoints of transfusion independence. The findings suggest that lower-risk patients with transfusion-dependent, non-del(5q) myelodysplastic...
IMerge Trial: Use of Imetelstat Reduces Transfusion Dependence in Lower-Risk MDS
In the primary analysis of the phase III randomized, double-blind, placebo-controlled IMerge trial, in those achieving the primary endpoint of 8-week transfusion independence, treatment with imetelstat significantly reduced transfusion dependence—for a median duration of 1 year—and improved a...
FDA Approves Dostarlimab-gxly Plus Chemotherapy for dMMR or MSI-H Endometrial Cancer
On July 31, the U.S. Food and Drug Administration (FDA) approved dostarlimab-gxly (Jemperli) with carboplatin and paclitaxel followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer that is mismatch repair–deficient (dMMR), as determined by an...
Ciltacabtagene Autoleucel vs Standard Care in Patients With Lenalidomide-Refractory Multiple Myeloma
In the phase III CARTITUDE-4 trial reported in The New England Journal of Medicine, San-Miguel et al found that receipt of ciltacabtagene autoleucel following bridging therapy significantly improved progression-free survival vs standard care in patients with lenalidomide-refractory multiple...
Expert Point of View: Barbara Burtness, MD
Discussing this study in her Highlights of the Day at the 2023 ASCO Annual Meeting was Barbara Burtness, MD, the Anthony N. Brady Professor of Medicine and Chief Translational Research Officer at Yale Cancer Center, New Haven, Connecticut. She noted that the premise of the FRAIL-IMMUNE trial...
Selinexor as Maintenance Therapy for p53 Wild-Type Endometrial Cancer
Long-term follow-up of selinexor maintenance therapy in patients with p53 wild-type endometrial cancer has demonstrated anticancer activity, according to data presented by Brian M. Slomovitz, MD, and colleagues during the ASCO Plenary Series: July 2023 Session (Abstract 427956). Results of the...
Primary Cancer and Noncancer Mortality Among Long-Term Survivors of Solid Tumors
In a study reported in JAMA Network Open, KC et al identified factors involved with primary cancer mortality vs noncancer mortality among long-term survivors of breast, prostate, and colorectal cancers. Study Details The study included data on 627,702 patients in the Surveillance, Epidemiology,...
Niraparib Maintenance in Newly Diagnosed Advanced Ovarian Cancer
In a Chinese phase III study reported in JAMA Oncology, Li et al found that niraparib maintenance therapy given with an individualized starting dose improved progression-free survival vs placebo in newly diagnosed patients with advanced ovarian cancer. Study Details In the double-blind multicenter...
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases
In a study reported in JAMA Oncology, Katipally et al found that an integrated clinical-molecular classification of colorectal cancer metastases to the liver distinguished risk groups for survival outcomes. Study Details The investigators had previously defined three biologically distinct molecular ...
Atezolizumab, Vemurafenib, and Cobimetinib in Patients With BRAF V600–Mutated Melanoma and CNS Metastases
A revised report of findings from the phase II TRICOTEL study of atezolizumab, vemurafenib, and cobimetinib in patients with melanoma and central nervous system (CNS) metastases was published in The Lancet Oncology by Reinhard Dummer, MD, and colleagues. The first version of trial findings,...
Addition of Nivolumab to SABR in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC
In the phase II I-SABR trial reported in The Lancet, Chang et al found that the addition of nivolumab to stereotactic ablative radiotherapy (SABR) improved event-free survival in patients with previously untreated stage I or II or isolated parenchymal recurrent node-negative non–small cell lung...
‘I Want to Kill You’
My patient threatened to kill me. I was in the middle of a busy medical oncology clinic. I was seeing her to discuss test results 1 week after I told her I was concerned that her cancer had returned. As I suspected, the test confirmed recurrent cancer, and this time, it was incurable. I walked into ...
Extended Follow-up of TROPiCS-02 Trial: Sacituzumab Govitecan in Metastatic Breast Cancer
Additional follow-up of the phase III TROPiCS-02 trial has upheld the progression-free and overall survival benefit seen with sacituzumab govitecan-hziy compared with physician’s choice of treatment in patients with endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast...
Roundup of Abstracts on New Therapies for Gastrointestinal Cancers From ASCO 2023
The 2023 ASCO Annual Meeting featured thousands of abstracts. In addition to our in-depth coverage of pivotal research from the meeting, The ASCO Post highlights the following studies of novel therapies for gastrointestinal cancers. Addition of Anti-TIGIT Agent in Unresectable Liver Cancer In the...
THOR Trial: Erdafitinib Improves Outcomes vs Chemotherapy in FGFR-Altered Advanced Urothelial Carcinoma
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib significantly improved overall survival, progression-free survival, and objective response rates compared with investigator’s choice of chemotherapy in patients with advanced urothelial cancers and FGFR2/3...
Stereotactic Radiosurgery Before Resection of Brain Metastases From Solid Tumors
In a study reported in JAMA Oncology, Prabhu et al identified outcomes and associated risk factors among patients receiving stereotactic radiosurgery (SRS) prior to resection of brain metastases from solid tumors. Study Details The study involved data from an international multicenter cohort...
CLL14: Long-Term Results of Fixed-Duration Venetoclax Plus Obinutuzumab in Elderly Patients With CLL
The 6-year follow-up of a landmark study has revealed significant treatment-free remissions and safety findings in elderly patients with chronic lymphocytic leukemia (CLL) and coexisting medical conditions.1 Long-term results of the CLL14 trial, presented during the European Hematology Association...
Overall Survival With Axicabtagene Ciloleucel in Large B-Cell Lymphoma: Results From ZUMA-7
As reported in The New England Journal of Medicine by Jason R. Westin, MD, and colleagues, the overall survival analysis from the phase III ZUMA-7 trial showed significant benefit with axicabtagene ciloleucel vs standard care in patients with early relapsed or refractory large B-cell lymphoma. The...
JUPITER-02: Toripalimab Plus Chemotherapy Improved Survival Outcomes for Some Patients With Advanced Nasopharyngeal Carcinoma
In the final overall survival analysis of the phase III JUPITER-02 trial, first-line treatment with toripalimab plus gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs chemotherapy alone in...
First-Line Atezolizumab vs Single-Agent Chemotherapy in Patients With Advanced NSCLC Ineligible for Platinum-Based Chemotherapy
In the phase III IPSOS trial reported in The Lancet, Lee et al found that first-line atezolizumab improved overall survival vs single-agent chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) who were ineligible for platinum-based chemotherapy. Study Details In the open-label...
Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer
In the phase III DARS study reported in The Lancet Oncology, Nutting et al found that dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) was associated with improved patient-reported swallowing function vs standard IMRT in newly diagnosed patients with head and neck cancer. Study...
Expert Point of View: Priyanka Bhateja, MD
Head and neck cancer specialist Priyanka Bhateja, MD, Assistant Professor in the Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, was encouraged by the findings of the Quarterback trial. As she noted in her comments for The ASCO Post, human papillomavirus...
Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer
De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Results of the nonrandomized phase II Quarterback trial suggest that this subset of patients may be...
Current Management of and Future Possibilities for Triple-Negative Breast Cancer
“Triple-negative breast cancer remains the most challenging subtype to treat because of its aggressive phenotype and limited treatment options,” stated Erica Michelle Stringer-Reasor, MD, who spoke at an education session on current approaches to treatment and future directions during the 2023 ASCO ...
Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial
As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit with osimertinib vs placebo in patients with resected EGFR-mutant non–small cell lung cancer (NSCLC)....
Expert Point of View: Gustavo Werutsky, MD and Lisa A. Carey, MD, ScM, FASCO
Invited discussant Gustavo Werutsky, MD, emphasized that health-related quality of life was consistently maintained in all phase III trials with fam-trastuzumab deruxtecan-nxki (T-DXd) in the metastatic breast cancer setting. Dr. Werutsky also highlighted the need for real-world data to understand...
Two Studies Highlight Benefits in Quality of Life and Symptom Management With Novel Treatments of Advanced Breast Cancer
Recent improvements in overall and progression-free survival for patients with HER2-positive and estrogen receptor–positive breast cancers have not come at the expense of quality of life or symptom management, according to a pair of studies presented at the European Society for Medical Oncology...
